Takeda Org Chart and Company Profile Report: Key Insights and Actionable Sales Intelligence

Takeda Org Chart & Company Profile: Key Insights & Overview

September 12, 2024

 

Takeda Pharmaceutical Company Limited
NYSE: TAK
1-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo 103-8668
Japan
Main Phone: 81 3 3278 2111
Website: https://www.takeda.com 
Industry Sector: Healthcare, Drug Manufacturers—Specialty & Generic
Full Time Employees: 49,095
Fiscal Year End: March 31, 2025
Annual Revenues: $29.42 Billion USD
#448 on the Fortune Global 500 (2024)
CEO: Christophe Weber, President & CEO

 

What is Takeda’s Mission Statement and Business Philosophy?

Takeda's mission is: "To discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet."

Its business philosophy is rooted in the following key principles:

• Takeda-ism: This is the core of Takeda's culture, encompassing values like integrity, fairness, honesty, and perseverance.
• Patient, Trust, Reputation, and Business: These four elements guide Takeda's decision-making and actions, ensuring a focus on patients and maintaining a strong reputation.
• People: Takeda values its employees and fosters a diverse, inclusive, and collaborative work environment.
• Leadership: Takeda leaders are expected to demonstrate strategic thinking, innovation, trust-building, and a focus on delivering results.
• These principles collectively shape Takeda's approach to business, driving its commitment to developing life-changing treatments and contributing to society.

What are Takeda’s growth strategies for 2024 and beyond?

Takeda's growth strategies for 2024 and beyond involve a multi-faceted approach focused on:   

1. Organizational Agility and Efficiency:

• Streamlining Operations: Takeda is implementing strategies to improve efficiency and reduce costs across its operations.   
• Leveraging Data and Technology: The company is investing in data analytics and digital tools to enhance decision-making and accelerate product development.   

2. Pipeline Advancement:

• Late-Stage Pipeline Focus: Takeda is prioritizing the development of its late-stage pipeline to bring innovative therapies to market more quickly.   
• Research and Development Investments: The company continues to invest in research and development to discover and develop new treatments.   

3. Core Operating Profit Margin Improvement:

• Cost Optimization: Takeda is actively seeking opportunities to reduce costs and improve profitability.   
• Procurement Efficiency: The company is optimizing its procurement processes to achieve cost savings and efficiencies.   

4. Sustainable Growth:

• Environmental, Social, and Governance (ESG) Focus: Takeda is committed to sustainable practices and is integrating ESG considerations into its business strategy.
• Long-Term Value Creation: The company aims to create long-term value for patients, the healthcare system, and society.   

Overall, Takeda's growth strategies are designed to drive sustainable growth, improve profitability, and deliver innovative therapies to patients. By focusing on organizational efficiency, pipeline advancement, and cost optimization, Takeda is well-positioned to achieve its growth objectives in the years to come.

 

 

What does the Takeda organizational structure look like in 2024?

Takeda's organizational structure in 2024 is a global, matrix-based model that aligns with its strategic goals. It is designed to foster collaboration, innovation, and efficiency across its various business units and regions.

Key components of the organizational structure include:

• Board of Directors: The Board of Directors oversees the company's management on a global scale.   
• Executive Team: The Executive Team, led by the Chief Executive Officer, is responsible for executing the company's strategy.   
• Business Units: Takeda is organized into several business units, each focused on a specific therapeutic area or region. These units are responsible for developing, manufacturing, and commercializing products.
• Global Functions: Global functions, such as research and development, manufacturing, supply chain, and marketing, provide support to the business units and ensure consistency across the company.
• Regional Operations: Takeda has a strong regional presence, with operations in various countries around the world. Regional teams are responsible for adapting the company's strategy to local market needs.   

The matrix structure allows for flexibility and responsiveness, enabling Takeda to adapt to changing market conditions and leverage its global expertise.

Who is the current CEO of Takeda?

Christophe Weber is the President, Chief Executive Officer (CEO), and Representative Director of Takeda, a global biopharmaceutical leader. His tenure at Takeda has been marked by significant transformation and growth, positioning the company as a major player in the healthcare industry.

Prior to joining Takeda in 2014, Weber spent over two decades at GlaxoSmithKline, holding various senior leadership roles across Europe, Asia, and the United States. This experience has equipped him with a deep understanding of the global healthcare landscape and a proven track record of driving business success.

Under Weber's leadership, Takeda has focused on expanding its global footprint, strengthening its research and development capabilities, and delivering innovative therapies to patients worldwide. His strategic vision has been instrumental in driving the company's growth and solidifying its position as a leading pharmaceutical company.

Beyond his professional accomplishments, Weber is a strong advocate for diversity and inclusion. He is committed to creating a workplace culture that values diverse perspectives and fosters a sense of belonging for all employees.

Weber's leadership and expertise have made a significant impact on Takeda, and his continued contributions to the company are expected to drive future success.

Who is the Chief Information Officer (CIO) at Takeda?

Gabriele Ricci is the Chief Data and Technology Officer at Takeda. This role effectively positions him as the Chief Information Officer (CIO) for the company. He was appointed to this position in February 2022 and is responsible for leading the transformation of Takeda's Data, Digital, and Technology division.

Have there been any executive leadership changes at Takeda in 2024?

One significant change announced in March 2024 was the appointment of Milano Furuta as the new Chief Financial Officer (CFO). Furuta succeeded Constantine Saroukos, who expressed his intention to retire. Furuta has been serving as the president of Takeda's Japan Pharma Business Unit.

Additionally, Takeda announced candidates for its Board of Directors at its 148th Ordinary General Meeting of Shareholders in June 2024. One of the proposed candidates was Milano Furuta, who was expected to join the Board if approved by shareholders.

These changes are part of Takeda's ongoing efforts to strengthen its leadership and position itself for future growth.

July 2, 2024

Takeda will lay off a further 220 employees in Massachusetts, the company disclosed in a June 27 WARN notice. Of those, 189 people will be let go from a location in Cambridge, and 31 are being laid off in Lexington. In total, Takeda has now laid off or announced plans to lay off more than 1,300 employees so far in 2024, on top of staffing cuts it made in 2023.

May 28, 2024

Takeda will undergo more layoffs, with 641 workers in Massachusetts set to get the ax, according to Endpoints News. A company spokesperson told Endpoints that the bulk of the layoffs will be in Cambridge, with 495, while 146 positions will also be eliminated in Lexington. Layoffs will begin in July and continue until March 2025. Takeda announced that it is undertaking a restructuring of over $900 million and has already committed to closing an R&D facility in San Diego, which employs more than 300 people. The Japanese pharma currently employs 36,893 people, according to LinkedIn, of which more than 18,000 are in the U.S.

May 22, 2024

Takeda is shuttering an R&D hub in San Diego that employs 324 people, according to a May 9 WARN notice. The layoffs, part of a broader restructuring by the global company, will take effect in July. The San Diego Union-Tribune noted that some of the affected employees will be offered jobs at Takeda’s offices in Massachusetts. It added that the San Diego facility concentrated on gastroenterology, inflammation and neuroscience.

 

March 12, 2024

Takeda Pharmaceuticals is shutting down R&D and manufacturing operations at a facility in Orth an der Donau, Austria, cutting 190 jobs in the process, Endpoints News reported, citing Austrian newspaper Kronen Zeitung. About 140 people will remain at the site in quality control as Takeda seeks to sell the property, which it picked up when it acquired Shire in 2019.

Who are Takeda’s top competitors in the marketplace?

Takeda is a major pharmaceutical company, and its top competitors in the global marketplace include:

• Novartis: Known for its innovative treatments in areas like oncology, ophthalmology, and cardiovascular disease.
• Merck & Co.: A global leader in prescription medicines, vaccines, and animal health products.
• Pfizer: A multinational pharmaceutical and biotechnology company, known for its vaccines and innovative treatments.
• Roche: A Swiss multinational healthcare company, specializing in pharmaceuticals and diagnostics.
• AstraZeneca: A global biopharmaceutical company, focused on discovery, development, and commercialization of prescription medicines.
• Sanofi: A French multinational pharmaceutical company, with a strong presence in vaccines, diabetes, and rare diseases.

These companies often compete with Takeda in various therapeutic areas, including oncology, gastroenterology,neuroscience, and rare diseases.

Who currently sits on the Takeda Board of Directors?

The current members of the Takeda Board of Directors are:
Christophe Weber
Representative Director - President & CEO
Milano Furuta
Director – Chief Financial Officer
Andrew S. Plump
Director - President, Research & Development
Masami Iijima
External Director - Chair of the Board meeting
Ian Clark
External Director
Steven Gillis
External Director
Emiko Higashi
External Director
John Maraganore
External Director
Michel Orsinger
External Director
Miki Tsusaka
External Director
Koji Hatsukawa
External Director - Chair of Audit & Supervisory Committee
Jean-Luc Butel
External Director - Audit & Supervisory Committee member
Yoshiaki Fujimori
External Director - Audit & Supervisory Committee member
Kimberly A. Reed
External Director - Audit & Supervisory Committee member

Who is on the Takeda executive leadership team in 2024?

Christophe Weber
Representative Director - President & CEO
Akiko Amakawa
Corporate Strategy Officer & CEO Chief of Staff
Andrew S. Plump
Director - President, Research & Development
Asuka Miyabashira​
President, Japan Pharma Business Unit​
Elaine Shannon
Global Quality Officer
Gabriele Ricci
Chief Data & Technology Officer
Giles Platford
President, Plasma-Derived Therapies Business Unit
Julie Kim
President, U.S. Business Unit, and U.S. Country Head
Lauren Duprey
Chief Human Resources Officer
Marcello Agosti
Global Business Development Officer
Milano Furuta
Director – Chief Financial Officer
Mwana Lugogo
Chief Ethics & Compliance Officer
Ramona Sequeira
President, Global Portfolio Division
Takako Ohyabu
Chief Global Corporate Affairs & Sustainability Officer
Teresa Bitetti
President, Global Oncology, Takeda
Thomas Wozniewski
Global Manufacturing & Supply Officer
Yoshihiro Nakagawa
Global General Counsel

What Technology Platforms have been deployed at Takeda?

Takeda has deployed a variety of technology platforms to support its business operations. Some of the notable platforms include:   

Cloud Platforms:

• Amazon Web Services (AWS): Takeda has leveraged AWS for its cloud computing needs, including infrastructure, storage, and data analytics.   
• Microsoft Azure: Azure is another cloud provider that Takeda utilizes for various applications and services.

Data Platforms:

• Seqster: Takeda has partnered with Seqster to build a patient data platform that combines information from electronic health records, genomic profiles, and wearable devices.   
• Other Data Platforms: Takeda likely uses additional data platforms to manage and analyze its vast amount of research and clinical data.

Digital Transformation:

• Digital Innovation Hub: Takeda has established an innovation hub to introduce digital solutions, artificial intelligence, robotics, automation, and analytics into its business.   
• Metaverse: Takeda has explored the metaverse through platforms like AltSpaceVR and other leading metaverse solutions.   

Other Platforms:

• Enterprise Resource Planning (ERP) Systems: Takeda likely uses ERP systems to manage its financial, human resources, and supply chain processes.   
• Customer Relationship Management (CRM) Systems: CRM systems help Takeda manage its interactions with customers and partners.   
• Research and Development (R&D) Platforms: Takeda uses specialized R&D platforms to support its drug discovery and development efforts.

Takeda SWOT Analysis

Takeda Pharmaceuticals, a global leader in the pharmaceutical industry, has a strong foundation built on decades of research and development. Here's a SWOT analysis to assess its strengths, weaknesses, opportunities, and threats:



STRENGTHS

• Strong Global Presence: Takeda has a significant global footprint, operating in various regions and markets. This allows them to capitalize on diverse growth opportunities.
• Extensive Research and Development: The company has a robust R&D pipeline, focusing on innovative therapies in areas such as oncology, gastroenterology, and rare diseases.
• Diverse Product Portfolio: Takeda's product portfolio includes a range of successful drugs across multiple therapeutic areas, providing a solid revenue base.
• Strategic Acquisitions: The company has a history of strategic acquisitions, which have helped expand its product offerings and geographic reach.
• Committed to Patients: Takeda's focus on patient-centricity has earned a positive reputation in the industry.

WEAKNESSES

• High Research and Development Costs: Developing new drugs is a costly endeavor, and Takeda, like other pharmaceutical companies, faces significant R&D expenses.
• Regulatory Challenges: Navigating complex regulatory landscapes in different countries can be time-consuming and costly.
• Generic Competition: As patents expire, Takeda may face increased generic competition for some of its key products.
• Dependence on a Few Blockbuster Drugs: While Takeda has a diverse portfolio, reliance on a few blockbuster drugs can make the company vulnerable to market fluctuations.

OPPORTUNITIES

• Emerging Markets: The growth of emerging markets, particularly in Asia, presents significant opportunities for Takeda to expand its market share.
• Biotechnology and Gene Therapy: Advancements in biotechnology and gene therapy offer potential for developing innovative treatments.
• Digital Health: Leveraging digital technologies can improve patient outcomes, streamline operations, and enhance market reach.
• Partnerships and Collaborations: Strategic partnerships with other companies, research institutions, or governments can accelerate drug development and market access.

THREATS

• Economic Downturns: Global economic uncertainties can impact healthcare spending and demand for pharmaceutical products.
• Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous global players vying for market share.
• Intellectual Property Challenges: Protecting intellectual property can be a challenge, especially in emerging markets.
• Regulatory Changes: Changes in healthcare policies and regulations can impact the profitability of pharmaceutical companies.

Takeda Pharmaceuticals is well-positioned to capitalize on growth opportunities while addressing its challenges.By leveraging its strengths, mitigating weaknesses, and seizing opportunities, the company can continue to be a leading player in the global pharmaceutical industry.

 

About Us
Founded in 2015, databahn is an account intelligence company headquartered in Nashua, New Hampshire. The databahn research team specialize in providing comprehensive and up-to-date information on Fortune 1000 and Global 2000 companies. databahn offers a range of information services, including deep dive company profiles, financial insights, news updates, competitive analysis, and accurate contact information. databahn's account intelligence is meticulously curated, enabling businesses to make informed decisions, identify sales opportunities, and gain a competitive edge. With the focus on accuracy, completeness, and timeliness, databahn serves as a valuable resource for sales and marketing professionals and other industries that require reliable and actionable insights on large & complex enterprise companies.